AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
acamprosate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 38 | 77337-76-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
The mechanism of action of acamprosate in maintenance of alcohol abstinence is not completely understood. Chronic alcohol exposure is hypothesized to alter the normal balance between neuronal excitation and inhibition. In vitro and in vivo studies in animals have provided evidence to suggest acamprosate may interact with glutamate and GABA neurotransmitter systems centrally, and has led to the hypothesis that acamprosate restores this balance.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 2 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 50 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 71.27 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BA (Bioavailability) | 11 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 0.30 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 3.75 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 1 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 3.20 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 | 49 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,CAMK2D,CDK1,CDK16,CDK3,CDK4,CDK6,CDK7,CDK9,CLK4,DDR1,DYRK1A,DYRK2,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IRAK1,IRAK3,JAK2,MAP2K6,MAP3K21,MAPK14,MAPK7,SIK2,STK16,STK33,SYK,TEK,TYRO3,ZAP70 | 34 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 29, 2004 | FDA | FOREST LABS |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Electrocardiogram QT prolonged | 132.59 | 45.44 | 43 | 900 | 72413 | 90555091 |
| Ventricular fibrillation | 130.36 | 45.44 | 30 | 913 | 14014 | 90613490 |
| Torsade de pointes | 82.08 | 45.44 | 21 | 922 | 15161 | 90612343 |
| Hyperhidrosis | 66.51 | 45.44 | 31 | 912 | 136274 | 90491230 |
| Intentional self-injury | 47.79 | 45.44 | 16 | 927 | 29318 | 90598186 |
| Alcoholism | 46.64 | 45.44 | 9 | 934 | 1791 | 90625713 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Anticoagulation drug level above therapeutic | 71.82 | 34.89 | 16 | 1085 | 2574 | 42617660 |
| Hepatitis acute | 56.37 | 34.89 | 17 | 1084 | 8958 | 42611276 |
| Delirium | 52.41 | 34.89 | 26 | 1075 | 52493 | 42567741 |
| Overdose | 42.68 | 34.89 | 29 | 1072 | 105235 | 42514999 |
| Coma | 40.44 | 34.89 | 22 | 1079 | 53532 | 42566702 |
| Intentional overdose | 38.47 | 34.89 | 21 | 1080 | 51435 | 42568799 |
| Wrong dose | 37.30 | 34.89 | 8 | 1093 | 1076 | 42619158 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Electrocardiogram QT prolonged | 113.44 | 36.04 | 50 | 1983 | 108910 | 110478356 |
| Ventricular fibrillation | 81.26 | 36.04 | 30 | 2003 | 41283 | 110545983 |
| Overdose | 72.60 | 36.04 | 48 | 1985 | 233746 | 110353520 |
| Anticoagulation drug level above therapeutic | 62.72 | 36.04 | 15 | 2018 | 4615 | 110582651 |
| Coma | 62.02 | 36.04 | 34 | 1999 | 117835 | 110469431 |
| Torsade de pointes | 61.90 | 36.04 | 21 | 2012 | 22579 | 110564687 |
| Alcoholism | 60.67 | 36.04 | 14 | 2019 | 3693 | 110583573 |
| Intentional overdose | 53.07 | 36.04 | 32 | 2001 | 132469 | 110454797 |
| Hepatitis acute | 45.80 | 36.04 | 16 | 2017 | 18750 | 110568516 |
| Hyperhidrosis | 45.24 | 36.04 | 33 | 2000 | 187265 | 110400001 |
| Intentional self-injury | 38.27 | 36.04 | 17 | 2016 | 37412 | 110549854 |
| Delirium | 37.69 | 36.04 | 26 | 2007 | 134999 | 110452267 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N07BB03 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS DRUGS USED IN ADDICTIVE DISORDERS Drugs used in alcohol dependence |
| MeSH PA | D000427 | Alcohol Deterrents |
| CHEBI has role | CHEBI:35469 | antidepressant |
| CHEBI has role | CHEBI:35474 | anxiolytic drug |
| CHEBI has role | CHEBI:35476 | antipsychotic agent |
| CHEBI has role | CHEBI:35703 | xenobiotic |
| CHEBI has role | CHEBI:35942 | neurotransmitter agent |
| CHEBI has role | CHEBI:78298 | environmental contaminant |
Related Drugs by ATC class:
N07BB Drugs used in alcohol dependence 4 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Alcoholism | indication | 7200002 | |
| Suicidal thoughts | contraindication | 6471006 | |
| Acute nephropathy | contraindication | 58574008 | |
| Impaired renal function disorder | contraindication | 197663003 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 0.21 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| GABA-A receptor alpha-1/beta-3/gamma-2 | Ion channel | POSITIVE MODULATOR | WOMBAT-PK | CHEMBL | |||||
| Glutamate [NMDA] receptor | Ion channel | ANTAGONIST | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4021476 | VUID |
| N0000148859 | NUI |
| D02780 | KEGG_DRUG |
| 77337-73-6 | SECONDARY_CAS_RN |
| 152761 | RXNORM |
| C0284941 | UMLSCUI |
| CHEBI:51041 | CHEBI |
| CHEMBL1201293 | ChEMBL_ID |
| CHEMBL2068724 | ChEMBL_ID |
| D000077443 | MESH_DESCRIPTOR_UI |
| DB00659 | DRUGBANK_ID |
| 7106 | IUPHAR_LIGAND_ID |
| 6473 | INN_ID |
| N4K14YGM3J | UNII |
| 71158 | PUBCHEM_CID |
| 17781 | MMSL |
| 205049 | MMSL |
| 50782 | MMSL |
| 59283 | MMSL |
| d04986 | MMSL |
| 4021476 | VANDF |
| 005217 | NDDF |
| 006125 | NDDF |
| 391698009 | SNOMEDCT_US |
| 391699001 | SNOMEDCT_US |
| 420804003 | SNOMEDCT_US |
| N4K14YGM3J | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Acamprosate Calcium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-6333 | TABLET, DELAYED RELEASE | 333 mg | ORAL | ANDA | 28 sections |
| Acamprosate Calcium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0615-8560 | TABLET, DELAYED RELEASE | 333 mg | ORAL | ANDA | 28 sections |
| Acamprosate Calcium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0904-7213 | TABLET, DELAYED RELEASE | 333 mg | ORAL | ANDA | 26 sections |
| Acamprosate Calcium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-636 | TABLET, DELAYED RELEASE | 333 mg | ORAL | ANDA | 28 sections |
| Acamprosate Calcium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60687-121 | TABLET, DELAYED RELEASE | 333 mg | ORAL | ANDA | 26 sections |
| Campral | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-4760 | TABLET, DELAYED RELEASE | 333 mg | ORAL | NDA | 29 sections |
| acamprosate calcium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68382-569 | TABLET, DELAYED RELEASE | 333 mg | ORAL | ANDA | 25 sections |
| Acamprosate Calcium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68462-435 | TABLET, DELAYED RELEASE | 333 mg | ORAL | ANDA | 26 sections |
| Acamprosate Calcium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69452-353 | TABLET, DELAYED RELEASE | 333 mg | ORAL | ANDA | 26 sections |
| acamprosate calcium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70518-4616 | TABLET, DELAYED RELEASE | 333 mg | ORAL | ANDA | 25 sections |
| acamprosate calcium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70771-1057 | TABLET, DELAYED RELEASE | 333 mg | ORAL | ANDA | 25 sections |